Fluoxetine for Major Depressive Disorder

Inspect the conclusion, its exact scope, the statements used to support it, and when each source was checked. This page does not add clinical advice or extend the published research beyond its stated scope.

Published assessment

Only this Treatment × Need pair is assessed here.

1 distinct published sources

Research suggests benefit in this exact scope

Published Sep 20, 2026 · revision 1

Reasoning and support

Open any source row to inspect scope and supporting text.

conclusion

The retained fluoxetine label reports placebo-controlled studies for major depressive disorder; this assessment does not determine personal suitability or compare fluoxetine with every alternative.

DailyMed fluoxetine hydrochloride label · checked Sep 19, 2026

Relationship: supports bounded conclusion

Scope: country:US

Pointer: /sections/4

Supporting passage: The efficacy of fluoxetine was studied in 5- and 6-week placebo-controlled trials with depressed adult and geriatric outpatients (≥ 18 years of age) whose diagnoses corresponded most closely to the DSM-III (currently DSM-IV) category of MDD.

Open source

Relationship source

Why this Treatment appears in the Need landscape, separate from the research conclusion.

DailyMed fluoxetine hydrochloride label · checked Sep 19, 2026

Relationship: label-reported clinical studies for the Need

Scope: country:US

Pointer: /sections/4

Supporting passage: The efficacy of fluoxetine was studied in 5- and 6-week placebo-controlled trials with depressed adult and geriatric outpatients (≥ 18 years of age) whose diagnoses corresponded most closely to the DSM-III (currently DSM-IV) category of MDD.

Open source

See something wrong? Tell us. Your note is private. We check sources before we change this page.